Menthandion-(3,5) | 94268-58-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: Menthandion-(3,5)
• 英文别名: p-menthane-3,5-dione；p-Menthan-3,5-dion；1-Methyl-4-isopropyl-cyclohexandion-(3.5)；2-Isopropyl-5-methylcyclohexane-1,3-dione；5-methyl-2-propan-2-ylcyclohexane-1,3-dione
• CAS: 94268-58-3
• 化学式: C₁₀H₁₆O₂
• 分子量: 168.236
• InChiKey: ZZQRHXWLKHSPRK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-amino-2-isopropyl-5-methyl-benzene-1,3-diol 、 、 5-异丙基-2-甲基苯-1,3-二醇 、 Menthandion-(3,5) 、 原甲酸三乙酯 、 硫酸 在 四氯化钛 氩 、 碳酸氢钠 、 水 、 二氯甲烷 、 Sodium sulfate-III 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以afforded 175 mg of 7-isopropyl-2,4-dimethyl-benzooxazol-6-ol的产率得到7-isopropyl-2,4-dimethyl-benzooxazol-6-ol
  参考文献：
  名称：

  Diaminopyrimidines as P2X3 and P2X2/3 antagonists

  摘要：

  本发明涉及一种用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的疾病的化合物和方法，所述方法包括向需要治疗的受体中注射有效量的公式（I）的化合物或其药学上可接受的盐、溶剂或前药，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。

  公开号：

  US07858632B2
• 作为产物：
  描述：

  Methyl 3,7-dimethyl-5-oxooctanoate 在 potassium tert-butylate 作用下， 以 乙醚 为溶剂， 反应 1.0h， 生成 Menthandion-(3,5)
  参考文献：
  名称：

  Pheromones and analogs from Neozeleboria wasps and the orchids that seduce them: a versatile synthesis of 2,5-dialkylated 1,3-cyclohexanediones

  摘要：

  Chiloglottone, a wasp pheromone and attractant of sexually deceptive Chiloglottis orchids, and several structural analogs were synthesized. The synthetic approach is facile, high yielding and versatile, enabling rapid divergence to generate dialkylated analogs of chiloglottone. The key transformation was an organocadmium-mediated desymmetrization of glutaric anhydride derivatives. This library of synthetic 2,5-dialkylated 1,3-cyclohexanediones may assist in future identification of natural products in further species. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2008.02.037

文献信息

• Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases
  申请人：Broka Allen Chris

  公开号：US20070049609A1

  公开（公告）日：2007-03-01

  Methods for treating respiratory and gastrointestinal diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.

  用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的呼吸系统和胃肠道疾病的方法，包括向有此需要的受试者施用有效量的式(I)化合物：或其药学上可接受的盐，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。
• PROCESS FOR PREPARING TAPINAROF
  申请人：Dermavant Sciences GmbH

  公开号：US20210024442A1

  公开（公告）日：2021-01-28

  The present invention provides processes for the preparation of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and novel intermediates used therein. In some embodiments the 3,5-Dihydroxy-4-isopropyl-trans-stilbene is prepared from (E)-2-chloro-2-isopropyl-5-styrylcyclohexane-1,3-dione. Also disclosed are crystal forms of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and pharmaceutical compositions comprising same.

  本发明提供了制备3,5-二羟基-4-异丙基-反-苯乙烯或其盐或溶剂的方法，以及其中使用的新型中间体。在某些实施例中，3,5-二羟基-4-异丙基-反-苯乙烯是从(E)-2-氯-2-异丙基-5-苯乙烯基环己烷-1,3-二酮制备的。此外，还公开了3,5-二羟基-4-异丙基-反-苯乙烯或其盐或溶剂的晶体形式以及包含其的药物组合物。
• DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS
  申请人：Broka Chris Allen

  公开号：US20110077242A1

  公开（公告）日：2011-03-31

  Compounds and methods for treating diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.

  本发明涉及化合物和方法，用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的疾病，其中所述方法包括向需要该治疗的受体中施用化合物I式的有效量，或其药学上可接受的盐、溶剂或前药，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。
• METHODS OF USING DIAMINOPYRIMIDINE AS P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES
  申请人：Broka Chris Allen

  公开号：US20120122859A1

  公开（公告）日：2012-05-17

  Methods for treating respiratory and gastrointestinal diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.

  治疗由P2X3和/或P2X2/3受体拮抗剂介导的呼吸道和胃肠道疾病的方法，包括向需要治疗的个体施用式(I)的化合物的有效量或其药学上可接受的盐，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如此定义。
• Methods of using diaminopyrimidine as P2X3 and P2X⅔ receptor modulators for treatment of respiratory and gastrointestinal diseases
  申请人：Broka Chris Allen

  公开号：US08524725B2

  公开（公告）日：2013-09-03

  Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.

  治疗由P2X3和/或P2X2/3受体拮抗剂介导的呼吸和胃肠疾病的方法，包括向需要该方法的受体中投与化合物的有效量，该化合物的公式为（I）或其药学上可接受的盐，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8的定义如本文所述。